Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)

• Status: Withdrawn
• Trial end date: 2013-10-01

Summary

The project was undertaking by Qilu Hospital of Shandong University and other 13 well-known hospitals in China. In order to report the efficacy and safety of Recombinant Human thrombopoietin combining with Rituximab for the treatment of adults with primary immune thrombocytopenia (ITP), compared to conventional high-dose dexamethasone therapy.

• Phase: Phase 3

Details

• Lead Sponsor: Shandong University
• Collaborators: Anhui Medical University; China Medical University, China; Shandong Provincial Hospital; Shenzhen Second People's Hospital; The Affiliated Hospital of the Chinese Academy of Military Medical Sciences; The First Affiliated Hospital of Dalian Medical University; Zhejiang Provincial Hospital of TCM
• Treatments: BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Rituximab